Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EnWave Sells Second Radiant Energy Vacuum Machine to Responsible Foods Ehf d.b.a. Naera Snacks: https://www.irw-press.at/prcom/images/messages/2021/54938/EnWave_05012020_ENPRcom.001.jpeg
EnWave Sells Second Radiant Energy Vacuum Machine to Responsible Foods Ehf d.b.a. Naera Snacks

Vancouver, B.C., January 5, 2021 - EnWave Corporation (TSX-V: ENW | FSE: E4U) (“EnWaveor theCompany - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today

EnWave’s Terpene Max™ REV™ Drying Process Surpasses Industry Averages for Room Dried Cannabis: https://www.irw-press.at/prcom/images/messages/2020/54571/08122020_EN_EnWave_Announces.001.jpeg
EnWave’s Terpene Max™ REV™ Drying Process Surpasses Industry Averages for Room Dried Cannabis

Vancouver, B.C., December 8th, 2020

 

EnWave Corporation (TSX-V: ENW | FSE: E4U) (“EnWave,” or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/)

announces

Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound for Clinical Trial

 

Vancouver, Canada - June 22, 2022 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with Contract Manufacturing

Former Bayer Senior Executive Joins Sirona Biochem Advisory Board

Vancouver, Canada - June 20, 2022 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (Sirona”) is pleased to announce that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June

LONDON, Ontario – June 15, 2022 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that D

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

 

Licenses Revolutionary Skin Care Compound TFC-1067

 

Vancouver, Canada - June 13, 2022 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (Sirona”) is pleased to announce it has

Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch SystemTM at American Diabetes Association 82nd Scientific Sessions 2022

-          Researchers from the Dr. Piotr Witkowski Laboratory at the University of Chicago presented updated data on six patients with type 1 diabetes and hypoglycemia unawareness

-         

Sernova Shares to Commence Trading on TSX on June 2, 2022

London, Ontario June 1, 2022Sernova Corp. (TSX-V:SVA; OTCQB:SEOVF; FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, is pleased to announce

EnWave Reports 2022 Second Quarter Consolidated Interim Financial Results

Vancouver, B.C., May 27th, 2022 - EnWave Corporation (TSX-V: ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) today reported

Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange

London, Ontario May 24, 2022 – Sernova Corp. (TSX-V:SVA; OTCQB:SEOVF; FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, is pleased to announce

EnWave to Report Second Quarter 2022 Financial Results on May 26, 2022 and Host Investor Conference Call

 

Vancouver, B.C., May 19th, 2022. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/), a global leader

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes

-          Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC- Based Insulin-Producing Beta Cells

-          Partners to Develop and Commercialize an

Scryb Wins Contract with Large Blockchain-based Cryptocurrency Exchange for Licence to Cybeats Cybersecurity Enterprise Software Platform

TORONTO, May 17, 2022Scryb Inc. (“Scryb'' or the “Company”) (CSE: SCYB, OTCQB: SCYRF, Frankfurt: EIY), is pleased to report on the signing of a software licence agreement for Cybeats

Medigene AG: Dr. Selwyn Ho appointed new CEO of Medigene

Experienced life sciences executive, physician and investor will lead Medigene starting 25 July 2022

 

Planegg/Martinsried (12.05.2022) - The Supervisory Board of Medigene AG (Medigene, FSE:

Scryb Announces Partnership with S&P 500 Multinational Cybersecurity Corporation

 

TORONTO, May 11, 2021 - Scryb Inc. (“Scryb'' or the “Company”) (CSE: SCYB, OTCQB: SCYRF, Frankfurt: EIY), is pleased to report on an agreement with an S&P 500 multinational cybersecurity

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022

 

LONDON, ONTARIO - May 9, 2022 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional

Sernova to Participate in Multiple U.S. Healthcare Investor Conferences

Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes

 

LONDON, ONTARIO - May 5, 2022 - Sernova

Medigene provides Q1 2022 update

Planegg/Martinsried (04.05.2022) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, today provides

Sernova Announces 2022 Annual General Meeting Results
Microsoft Word - Sernova 2022 AGM Results Release April 29, 2022.docx

LONDON, ONTARIO April 29, 2022 Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical stage regenerative medicine

EnWave Reports Successful Injunction Application Against Former CEO

Vancouver, BC, April 26, 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) received today the

Medigene publication details augmentation of PRAME-specific TCR-4 by PD1-41BB switch receptor

Planegg/Martinsried (25.04.2022) - Medigene AG (http://www.medigene.com) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer

Cybeats Recognized as a Representative Provider in 2022 Gartner® Innovation Insight for SBOMs Report

 

 

TORONTO, April 22, 2022 – Scryb Inc. (“Scryb'' or the “Company”) (CSE: SCYB, OTCQB: SCYRF, Frankfurt: EIY), is pleased to report that Cybeats has been recognized as a Representative

Scryb Reports on Cybersecurity Trial Evaluation with Multinational Infrastructure Company

TORONTO, April 20, 2022 – Scryb Inc. (“Scryb'' or the “Company”) (CSE: SCYB, OTCQB: SCYRF, Frankfurt: EIY), is pleased to report on the signing of a software evaluation licence agreement with

Medigene participates at upcoming conferences

Planegg/Martinsried (13.04.2022) - Medigene AG (http://www.medigene.com) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer